SCHEDULE: Millennium Management Reduces Avalo Therapeutics Stake

Millennium Management LLC and affiliates reported a 4.9% passive stake in Avalo Therapeutics, Inc., having ceased to be beneficial owners of over 5% by the filing date.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander collectively reported beneficial ownership of 905,798 shares of Avalo Therapeutics, Inc. common stock.
• This represents 4.9% of the outstanding class of securities, with a par value of $0.001 per share.
• The reporting persons acquired beneficial ownership of more than 5% on January 28, 2026, which triggered the filing requirement.
• However, by the filing date of February 2, 2026, they had ceased to be beneficial owners of more than 5% of the outstanding common stock.
• The shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers controlled by Millennium Group Management LLC and Israel A. Englander.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of Avalo Therapeutics, Inc.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as slightly negative due to the reduction of a significant institutional stake from above 5% to 4.9%, potentially indicating a decreased conviction by Millennium Management.

Positives

• Millennium Management, a prominent investment firm, previously held a stake exceeding 5% in Avalo Therapeutics, indicating prior institutional interest.

Negatives

• The reporting persons ceased to be beneficial owners of more than 5% of Avalo Therapeutics by the filing date, reducing their stake to 4.9%. This suggests a reduction in their position from a higher level.

Risks

• The reduction in Millennium Management's stake from over 5% to 4.9% could signal a decreased conviction in Avalo Therapeutics by a significant institutional investor.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that institutional ownership disclosures like this Schedule 13G provide transparency into significant investor positions. While Millennium Management's stake reduction to below 5% might be a routine portfolio adjustment, it's a data point for investors tracking institutional sentiment in the biotechnology sector, where companies like Avalo Therapeutics often see dynamic shifts in ownership.

Stakeholder Impact

• Shareholders gain transparency regarding the ownership structure and changes in significant institutional holdings.
• Potential impact on investor sentiment due to a prominent institutional investor reducing its stake.

Key Dates

Recommendation

The filing indicates a reduction in a significant institutional stake, moving from above 5% to 4.9%. While this is a passive investment and not an activist move, the reduction by a firm like Millennium Management could signal a slight decrease in conviction. However, it's not a complete divestment, suggesting a 'hold' stance as investors await further operational news from Avalo Therapeutics.

Keywords

Avalo Therapeutics, Millennium Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, ATX